May 23, 2026 08:08 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Honoured to visit the Missionaries of Charity today, says Rubio after Kolkata visit, arrives in Delhi | Marco Rubio's India visit begins in Kolkata: Trade, defence and Quad talks take centre stage | Third fuel price hike in India in 10 days: Here’s what you’ll pay now | Big twist in RG Kar case! Calcutta HC orders fresh probe into evidence destruction allegations | Pulwama mastermind Hamza Burhan shot dead in PoK by unknown gunmen: Reports | NIA arrests Kolkata man for spying for Pakistan intelligence network | Cockroach Janta Party X handle withheld! Founder Abhijeet Dipke launches comeback account | Bengal govt makes Vande Mataram compulsory in all madrasas, extends school directive | RBI on alert! Interest rate hike may be coming as rupee crashes to fresh low | Big relief for Maharashtra employees! Fadnavis govt hikes DA to 60%
South Korea

South Korea OKs clinical trial of COVID-19 Plasma Therapy - Reports

| @indiablooms | Aug 20, 2020, at 07:34 pm

Moscow/Sputnik: South Korea green-lighted on Thursday phase 2 of a clinical trial of COVID-19 plasma treatment by firm GC Pharma, Yonhap reported.

The Ministry of Food and Drug Safety has skipped phase one of the trial, as the therapy itself is well-known and considered to be safe.

Several hospitals will start administering the therapy to patients who would volunteer to accept the treatment.

In total, clinical trials for 14 coronavirus treatments and two vaccines are currently underway in South Korea, according to the news agency. 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.